280 related articles for article (PubMed ID: 9354459)
1. Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen.
Denmeade SR; Lou W; Lövgren J; Malm J; Lilja H; Isaacs JT
Cancer Res; 1997 Nov; 57(21):4924-30. PubMed ID: 9354459
[TBL] [Abstract][Full Text] [Related]
2. Characterization of prostate-specific antigen proteolytic activity on its major physiological substrate, the sperm motility inhibitor precursor/semenogelin I.
Robert M; Gibbs BF; Jacobson E; Gagnon C
Biochemistry; 1997 Apr; 36(13):3811-9. PubMed ID: 9092810
[TBL] [Abstract][Full Text] [Related]
3. Enzymatic action of prostate-specific antigen (PSA or hK3): substrate specificity and regulation by Zn(2+), a tight-binding inhibitor.
Malm J; Hellman J; Hogg P; Lilja H
Prostate; 2000 Oct; 45(2):132-9. PubMed ID: 11027412
[TBL] [Abstract][Full Text] [Related]
4. Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models.
Denmeade SR; Sokoll LJ; Chan DW; Khan SR; Isaacs JT
Prostate; 2001 Jun; 48(1):1-6. PubMed ID: 11391681
[TBL] [Abstract][Full Text] [Related]
5. The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.
Garsky VM; Lumma PK; Feng DM; Wai J; Ramjit HG; Sardana MK; Oliff A; Jones RE; DeFeo-Jones D; Freidinger RM
J Med Chem; 2001 Nov; 44(24):4216-24. PubMed ID: 11708923
[TBL] [Abstract][Full Text] [Related]
6. A prostate-specific antigen activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancer.
Chandran SS; Nan A; Rosen DM; Ghandehari H; Denmeade SR
Mol Cancer Ther; 2007 Nov; 6(11):2928-37. PubMed ID: 18025277
[TBL] [Abstract][Full Text] [Related]
7. Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen.
Denmeade SR; Nagy A; Gao J; Lilja H; Schally AV; Isaacs JT
Cancer Res; 1998 Jun; 58(12):2537-40. PubMed ID: 9635575
[TBL] [Abstract][Full Text] [Related]
8. Semenogelin I and semenogelin II, the major gel-forming proteins in human semen, are substrates for transglutaminase.
Peter A; Lilja H; Lundwall A; Malm J
Eur J Biochem; 1998 Mar; 252(2):216-21. PubMed ID: 9523691
[TBL] [Abstract][Full Text] [Related]
9. Enzymatic action of human glandular kallikrein 2 (hK2). Substrate specificity and regulation by Zn2+ and extracellular protease inhibitors.
Lövgren J; Airas K; Lilja H
Eur J Biochem; 1999 Jun; 262(3):781-9. PubMed ID: 10411640
[TBL] [Abstract][Full Text] [Related]
10. Biological activity of prostate-specific antigen isolated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and electroelution.
Tessmer U; Quack T; Donn F; Leuner A; Dernick R
Electrophoresis; 1995 May; 16(5):793-9. PubMed ID: 7588564
[TBL] [Abstract][Full Text] [Related]
11. Characterization of semenogelin II and its molecular interaction with prostate-specific antigen and protein C inhibitor.
Kise H; Nishioka J; Kawamura J; Suzuki K
Eur J Biochem; 1996 May; 238(1):88-96. PubMed ID: 8665956
[TBL] [Abstract][Full Text] [Related]
12. Substrate specificity of prostate-specific antigen (PSA).
Coombs GS; Bergstrom RC; Pellequer JL; Baker SI; Navre M; Smith MM; Tainer JA; Madison EL; Corey DR
Chem Biol; 1998 Sep; 5(9):475-88. PubMed ID: 9751643
[TBL] [Abstract][Full Text] [Related]
13. Separation of enzymatically active and inactive prostate-specific antigen (PSA) by peptide affinity chromatography.
Wu P; Stenman UH; Pakkala M; Närvänen A; Leinonen J
Prostate; 2004 Mar; 58(4):345-53. PubMed ID: 14968435
[TBL] [Abstract][Full Text] [Related]
14. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors.
Christensson A; Laurell CB; Lilja H
Eur J Biochem; 1990 Dec; 194(3):755-63. PubMed ID: 1702714
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer.
Denmeade SR; Jakobsen CM; Janssen S; Khan SR; Garrett ES; Lilja H; Christensen SB; Isaacs JT
J Natl Cancer Inst; 2003 Jul; 95(13):990-1000. PubMed ID: 12837835
[TBL] [Abstract][Full Text] [Related]
16. In vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenografts.
Khan SR; Denmeade SR
Prostate; 2000 Sep; 45(1):80-3. PubMed ID: 10960846
[TBL] [Abstract][Full Text] [Related]
17. Activation of latent protease function of pro-hK2, but not pro-PSA, involves autoprocessing.
Denmeade SR; Lövgren J; Khan SR; Lilja H; Isaacs JT
Prostate; 2001 Jul; 48(2):122-6. PubMed ID: 11433422
[TBL] [Abstract][Full Text] [Related]
18. Regulation of the enzymatic activity of prostate-specific antigen and its reactions with extracellular protease inhibitors in prostate cancer.
Lilja H
Scand J Clin Lab Invest Suppl; 1995; 220():47-56. PubMed ID: 7544478
[TBL] [Abstract][Full Text] [Related]
19. A 5-fluorodeoxyuridine prodrug as targeted therapy for prostate cancer.
Mhaka A; Denmeade SR; Yao W; Isaacs JT; Khan SR
Bioorg Med Chem Lett; 2002 Sep; 12(17):2459-61. PubMed ID: 12161157
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo.
Denmeade SR; Litvinov I; Sokoll LJ; Lilja H; Isaacs JT
Prostate; 2003 Jun; 56(1):45-53. PubMed ID: 12746846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
